CORONA Remedies Limited announced robust financial performance for the second quarter and first half of FY27. Revenue surged by 22% year-on-year in Q2 FY27, reaching INR441 crores. The company’s India business continued its strong trajectory, growing by 22.9% in Q2 FY27. Profit after tax also saw a healthy increase of 15.3% to INR60 crores in Q2 FY27.
CORONA Remedies Limited Q2 and H1 FY27 Earnings Call Summary
CORONA Remedies Limited has disclosed strong financial results for the second quarter (Q2) and the first half (H1) of the financial year 2027 (FY27). The company reported a significant revenue growth of 22% year-on-year for Q2 FY27, with revenues standing at INR441 crores compared to INR361 crores in Q2 FY26. This growth reflects the company’s consistent performance and market position.
Financial Highlights
Q2 FY27 Performance
- Revenue: INR441 crores (up 22.2% YoY)
- India Business Revenue Growth: 22.9% YoY
- EBITDA: INR96 crores (up 22.3% YoY)
- EBITDA Margin: 21.7%
- Profit After Tax (PAT): INR60 crores (up 15.3% YoY)
- PAT Margin: 13.7%
H1 FY27 Performance
- EBITDA Growth: 27.5% YoY
- EBITDA Margin: 21.9%
- PAT: INR120 crores (up 22.2% YoY)
- PAT Margin: 13.9%
- Return on Capital Employed (ROCE): 49.8%
- Return on Equity (ROE): 32.9%
Operational and Strategic Insights
The company highlighted its strong performance in the Indian pharmaceutical market, which continues to show momentum with low to mid-double-digit growth. CORONA Remedies has outperformed the market, with its India business growing at 22.8% in H1 FY27. The chronic segment, a key area for CORONA, grew by approximately 29%, significantly outpacing the market segment’s growth.
Management emphasized a growth strategy built on four pillars: strengthening core therapies, brand building, disciplined operational excellence, and investing in the future. The company is also exploring expansion into new therapeutic areas such as infertility, nephrology, gastroenterology, spine, and rheumatology, considering both organic and inorganic routes.
Regarding recent acquisitions, the Wokadine brand integration is proceeding, with CORONA aiming for a 25% CAGR for Wokadine over 3-4 years. The company also discussed its international expansion plans, focusing on niche markets like hormones, with an aim to prepare 10-12 dossiers for regulated and semi-regulated markets over the next 2-3 years.
The company also addressed questions on price growth, new introductions, and market strategy, reiterating its focus on its 33 core ‘Engine Brands’ which contribute approximately 79% of the business and are growing at 22%. Export business for Q2 FY27 was INR12.6 crores, with H1 FY27 exports at INR25.3 crores. The company anticipates closing INR60-65 crores in international business this year, with a 15% growth expected next year.
CORONA Remedies also commented on regulatory aspects, noting that price regulation through NLEM and trade margin caps have not significantly impacted the company as of now, with NLEM portfolio contribution at around 7.5%.
Source: BSE
